LIGAND PHARMACEUTICALS INC
For the period ended Dec 31, 2023. Filed Feb 29, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 29, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 2. Properties
| Item 2. | Properties |
|---|
The following table summarizes our principal facilities leased as of December 31, 2023, including the location and size of each facility, and their designated use. We believe our facilities are adequate for our current and near-term needs, and we will be able to locate additional facilities, as needed.
| Location | Approximate Square Feet | Operation | Lease Expiration Date |
|---|---|---|---|
| Jupiter, FL | 1,650 | Corporate headquarter | October 2026 |
| San Diego, CA | 6,850 | Office | March 2029 |
| Boston, MA(1) | 6,840 | Office | June 2029 |
| Las Vegas, NV | 4,100 | Office | April 2028 |
| Lawrence, KS | 3,700 | Office and laboratory | August 2032 |
| Durham, NC | 19,300 | Office and laboratory | January 2032 |
(1) Including lease executed in November 2023 with occupancy expected in approximately the second quarter of 2024.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.